Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02777632
Other study ID # 2652010
Secondary ID
Status Completed
Phase N/A
First received May 17, 2016
Last updated February 2, 2017
Start date January 2014
Est. completion date November 2015

Study information

Verified date February 2017
Source Ain Shams University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this work was to study the incidence, types, risk factors and causative organisms of bacterial infections in HCV Egyptian patients following Liver Transplantation. Moreover, to identify the emerging resistant strains and their proper antimicrobial therapy


Description:

This prospective descriptive study has been done at Tropical Medicine department in the period between January 2014 to November 2015.

After the approval of the scientific and ethical committee of Ain Shams University Hospital, Patients with HCV positive end stage liver disease (ESLD) eligible for liver transplantation Ain Shams Center for Organ Transplant (ASCOT); Ain Shams University, (fulfilling the inclusion criteria) were included in the current study. Forty five patients were recruited and each one was followed-up during a period of 3 months following transplantation.

Included patients were divided into 2 groups:

Group 1 included patients who had a postoperative single episode of infection. Group 2 included those patients who had more than 1 episode of postoperative bacterial infection whom were further evaluated for the presence of emerging strains and/or antibiotic resistance.


Recruitment information / eligibility

Status Completed
Enrollment 45
Est. completion date November 2015
Est. primary completion date November 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

- Egyptian nationality.

- Accepting participation in the current study and signing a written consent form

- Age between 18-60 Years, including males and females.

Exclusion Criteria:

- Patients who refused to be enrolled in the study.

- Patients with other etiologies for end-stage liver disease (HBV, PBC…)

- Patients with preoperative infections, infections within 48 h after transplantation or early post-operative death

Study Design


Intervention

Procedure:
Living donor liver transplantation


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Ain Shams University

Outcome

Type Measure Description Time frame Safety issue
Primary Determine the types of early bacterial infections following LDLT, recurrent and resistant infections all were confirmed by cultures. Bile, abdominal drains, blood stream infection, urinary tract infection or chest infection. Within the first 90 days after the operation
Primary Assessment of risk factors for occurrence of recurrent bacterial infections Independent risk factors for infections The first 3 months following LDLT
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05047406 - Bacillus Clausii in Liver Transplantation Phase 2
Completed NCT02463214 - Prevention of Healthcare Associated Infections in Bone Marrow Transplant Patients N/A
Recruiting NCT05198570 - Pharmacokinetics of Intravenous Acyclovir in Oncologic Paediatric Patients
Completed NCT01808456 - Standard-dose Versus High-dose Flu Vaccine in Solid Organ Transplant. Phase 4
Suspended NCT01301118 - Graft Take and Microbiology in Burns N/A
Completed NCT00610961 - Induction Related BK Viremia in Renal Transplant Patients Phase 4
Recruiting NCT05215327 - High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients Phase 2
Recruiting NCT05193058 - Description of Lung Transplant Patients With Microbiologically Documented Stenotrophomonas Maltophilia Pneumonia and Impact of Treatment on Outcome
Unknown status NCT01983761 - Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation Phase 1/Phase 2
Active, not recruiting NCT02811835 - TransplantLines Food and Nutrition Biobank and Cohort Study (TxL-FN) N/A
Completed NCT01471444 - Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Phase 3
Enrolling by invitation NCT01349738 - Asymptomatic Bacteriuria & Risk of Urinary Tract Infection in Renal Transplants N/A
Terminated NCT00473824 - Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation Phase 2
Completed NCT01276457 - Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients Phase 3
Completed NCT00177801 - Organ Transplant Infection Prevention and Detection Project Phase 4
Completed NCT02328963 - Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A Phase 4
Recruiting NCT04320303 - CMV Infection and Immune Intervention After Transplantation N/A
Active, not recruiting NCT01295645 - Cidofovir Versus Best Supportive Care for Hemorrhagic Cystitis Phase 2
Completed NCT02329808 - Clinical Validation of a Dried Blood Spot Method for Analysis of Immunosuppressives and Antifungals in Pediatrics
Completed NCT01471067 - Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies Phase 1